Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul:69:103427.
doi: 10.1016/j.ebiom.2021.103427. Epub 2021 Jun 20.

Mesenchymal stem/stromal cell-based therapy for the treatment of rheumatoid arthritis: An update on preclinical studies

Mercedes Lopez-Santalla  1 , Juan A Bueren  2 , Marina I Garin  3
Affiliations
Review

Mesenchymal stem/stromal cell-based therapy for the treatment of rheumatoid arthritis: An update on preclinical studies

Mercedes Lopez-Santalla et al. EBioMedicine. 2021 Jul.

Abstract

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by synovial inflammation and progressive joint destruction and is a primary cause of disability worldwide. Despite the existence of numerous anti-rheumatic drugs, a significant number of patients with RA do not respond or are intolerant to current treatments. Mesenchymal stem/stromal cell (MSCs) therapy represents a promising therapeutic tool to treat RA, mainly attributable to the immunomodulatory effects of these cells. This review comprises a comprehensive analysis of the scientific literature related to preclinical studies of MSC-based therapy in RA to analyse key aspects of current protocols as well as novel approaches which aim to improve the efficacy of MSC-based therapy.

Keywords: Animal models; Improvements in MSC-based therapy; Mesenchymal stem/stromal cells; Protocols; Rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest None.

Figures

Fig 1
Fig. 1
Published preclinical studies of RA with MSC-based therapy classified according to the arthritis models and publication date. Data are expressed as percentages (%).
Fig 2
Fig. 2
Published preclinical studies of RA with MSC-based therapy classified according to the tissue sources. Data are expressed as percentages (%).
Fig 3
Fig. 3
Published preclinical studies of RA with MSC-based therapy classified according to the MHC context. Data are expressed as percentages (%).
Fig 4
Fig. 4
Published preclinical studies of RA with MSC-based therapy classified according to the route of administration. Data are expressed as percentages (%).
Fig 5
Fig. 5
Distribution of preclinical studies of RA with MSC therapy according to the time of treatment with MSCs related to the disease onset (a), MSC dose per mouse (b) and MSC dosage tested (c). Data are expressed in percentage (%).
See this image and copyright information in PMC

References

    1. Firestein G.S., McInnes I.B. Immunopathogenesis of rheumatoid arthritis. Immunity. 2017 doi: 10.1016/j.immuni.2017.02.006. - DOI - PMC - PubMed
    1. Smolen J.S., Aletaha D., McInnes I.B. Rheumatoid arthritis. Lancet. 2016 doi: 10.1016/S0140-6736(16)30173-8. - DOI - PubMed
    1. Otón T., Carmona L. The epidemiology of established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2019;33 doi: 10.1016/j.berh.2019.101477. - DOI - PubMed
    1. Singh J.A., Saag K.G., Bridges S.L., Akl E.A., Bannuru R.R., Sullivan M.C. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016 doi: 10.1002/acr.22783. - DOI - PubMed
    1. Smolen J.S., Landewé R.B.M., Bijlsma J.W.J., Burmester G.R., Dougados M., Kerschbaumer A. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020 doi: 10.1136/annrheumdis-2019-216655. - DOI - PubMed

MeSH terms